Show simple item record

dc.contributor.authorJones, Joanna
dc.contributor.authorWillis, Mark
dc.contributor.authorColes, Alasdair
dc.date.accessioned2018-11-22T15:46:25Z
dc.date.available2018-11-22T15:46:25Z
dc.date.issued2018-11
dc.identifier.issn1477-0970
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285728
dc.description.abstractDespite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report 3 (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
dc.publisherSAGE Publications
dc.titleSarcoidosis following alemtuzumab treatment for multiple sclerosis
dc.typeArticle
prism.publicationNameMultiple Sclerosis
dc.identifier.doi10.17863/CAM.33073
dcterms.dateAccepted2018-06-11
rioxxterms.versionofrecord10.1177/1352458518790391
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-06-11
dc.contributor.orcidJones, Joanna [0000-0003-4974-1371]
dc.contributor.orcidColes, Alasdair [0000-0003-4738-0760]
dc.identifier.eissn1477-0970
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (G1100114)
cam.issuedOnline2018-10-11


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record